<scp>EAACI</scp> guidelines on allergen immunotherapy: Hymenoptera venom allergy

  • G. J. Sturm
    Department of Dermatology and Venerology Medical University of Graz Graz Austria
  • E.‐M. Varga
    Department of Paediatric and Adolescent Medicine Respiratory and Allergic Disease Division Medical University of Graz Graz Austria
  • G. Roberts
    The David Hide Asthma and Allergy Research Centre St Mary's Hospital, Newport, Isle of Wight NIHR Biomedical Research Centre University Hospital Southampton NHS Foundation Trust Southampton UK
  • H. Mosbech
    Allergy Clinic Copenhagen University Hospital Gentofte Gentofte Denmark
  • M. B. Bilò
    Allergy Unit Department of Internal Medicine University Hospital of Ancona Ancona Italy
  • C. A. Akdis
    Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Zurich Switzerland
  • D. Antolín‐Amérigo
    Servicio de Enfermedades del Sistema Inmune‐Alergia Departamento de Medicina y Especialidades Médicas Hospital Universitario Príncipe de Asturias Universidad de Alcalá Madrid Spain
  • E. Cichocka‐Jarosz
    Department of Pediatrics Jagiellonian University Medical College Krakow Poland
  • R. Gawlik
    Department of Internal Medicine, Allergy and Clinical Immunology Medical University of Silesia Katowice Poland
  • T. Jakob
    Department of Dermatology and Allergology University Medical Center Gießen and Marburg (UKGM) Justus Liebig University Gießen Gießen Germany
  • M. Kosnik
    Medical Faculty Ljubljana University Clinic of Respiratory and Allergic Diseases Golnik Ljubljana Slovenia
  • J. Lange
    Department of Pediatric Pneumonology and Allergy Medical University of Warsaw Warsaw Poland
  • E. Mingomataj
    Department of Allergology & Clinical Immunology Mother Theresa School of Medicine Tirana Albania
  • D. I. Mitsias
    Department of Allergy and Clinical Immunology 2nd Paediatric Clinic University of Athens Athens Greece
  • M. Ollert
    Department of Infection and Immunity Luxembourg Institute of Health (LIH) Strassen Luxembourg
  • J. N. G. Oude Elberink
    Department of Allergology and Internal Medicine University of Groningen University Medical Hospital Groningen & Groningen Research Center for Asthma and COPD (GRIAC) Groningen The Netherlands
  • O. Pfaar
    Department of Otorhinolaryngology, Head and Neck Surgery Medical Faculty Mannheim Universitätsmedizin Mannheim Heidelberg University Heidelberg Germany
  • C. Pitsios
    Medical School University of Cyprus Nicosia Cyprus
  • V. Pravettoni
    UOC Clinical Allergy and Immunology ‐ IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
  • F. Ruëff
    Klinik und Poliklinik für Dermatologie und Allergologie Klinikum der Universität München Munich Germany
  • B. A. Sin
    Department of Pulmonary Diseases Division of Immunology and Allergy Faculty of Medicine Ankara University Ankara Turkey
  • I. Agache
    Faculty of Medicine Department of Allergy and Clinical Immunology Transylvania University Brasov Brasov Romania
  • E. Angier
    Department of Immunology and Allergy Northern General Hospital Sheffield UK
  • S. Arasi
    Department of Pediatrics Allergy Unit University of Messina Messina Italy
  • M. A. Calderón
    Section of Allergy and Clinical Immunology Imperial College London National Heart and Lung Institute Royal Brompton Hospital London UK
  • M. Fernandez‐Rivas
    Allergy Department Hospital Clínico San Carlos IdISSC Madrid Spain
  • S. Halken
    Hans Christian Andersen Children's Hospital Odense University Hospital Odense Denmark
  • M. Jutel
    Wroclaw Medical University Wroclaw Poland
  • S. Lau
    Department of Pediatric Pneumology and Immunology Charité Universitätsmedizin Berlin Germany
  • G. B. Pajno
    Department of Pediatrics Allergy Unit University of Messina Messina Italy
  • R. van Ree
    Departments of Experimental Immunology and of Otorhinolaryngology Academic Medical Center University of Amsterdam Amsterdam The Netherlands
  • D. Ryan
    Usher Institute of Population Health Sciences and Informatics University of Edinburgh Edinburgh UK
  • O. Spranger
    Austrian Lung Union Vienna Austria
  • R. G. van Wijk
    Section of Allergology Department of Internal Medicine Erasmus MC Rotterdam Rotterdam The Netherlands
  • S. Dhami
    Evidence‐Based Health Care Ltd Edinburgh UK
  • H. Zaman
    School of Pharmacy University of Bradford Bradford UK
  • A. Sheikh
    Asthma UK Centre for Applied Research Usher Institute of Population Health Sciences and Informatics University of Edinburgh Edinburgh UK
  • A. Muraro
    Food Allergy Referral Centre Veneto Region Department of Women and Child Health Padua General University Hospital Padua Italy

Description

<jats:title>Abstract</jats:title><jats:p>Hymenoptera venom allergy is a potentially life‐threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic‐allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life‐threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H<jats:sub>1</jats:sub>‐antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (<jats:styled-content style="fixed-case">EAACI</jats:styled-content>) Taskforce on Venom Immunotherapy as part of the <jats:styled-content style="fixed-case">EAACI</jats:styled-content> Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence‐based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta‐analysis and produced using the Appraisal of Guidelines for Research and Evaluation (<jats:styled-content style="fixed-case">AGREE II</jats:styled-content>) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom‐allergic children and adults to prevent further moderate‐to‐severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence‐based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.</jats:p>

Journal

  • Allergy

    Allergy 73 (4), 744-764, 2017-12-05

    Wiley

Citations (3)*help

See more

Report a problem

Back to top